| Overview |
| bsm-62940r |
| Phospho-POLR2A (Ser5) Recombinant Antibody |
| WB, IHC-P, IHC-F, IP, IF, Flow-Cyt, ICC/IF |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human POLR2A around the phosphorylation site of S5 |
| Ser5 |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 5430 |
| P24928 |
| Nucleus |
| POLR2A; POLR2; RNA polymerase II CTD repeat YSPTSPS. |
| During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IP |
1-2ug |
| IF |
|
| Flow-Cyt |
1ug/Test |
| ICC/IF |
1:50-100 |